Suspensions of peripheral blood mononuclear cells (PBMC), monocytes, T or B lymphocytes, platelets or granulocytes, and cell-depleted supernatant fluids of these suspensions inhibited activation of Hageman factor (HF, Factor XII) by ellagic acid, a property not shared by erythrocytes. PBMC also inhibited HF activation by glass or sulfatides. Contaminating platelets may have contributed to inhibition by PBMC.
ble agent or agents are detected in cell-depleted supernatant fluid separated from cell suspensions. The inhibitory properties are associated with proteins that are synthesized by the cells. The biological significance of the inhibitory agent or agents in deterring intravascular coagulation remains to be determined.
Methods
Heparinized blood was prepared by drawing 50 ml blood from the antecubital vein of human subjects into polypropylene syringes containing 1 ml heparin (1,000 NIH U/ml); the donors were normal adults except for a 19-yr-old woman with idiopathic aplastic anemia (5, 000 platelets/tal). Citrated blood was prepared by transferring 10 ml normal venous blood, drawn into a polypropylene syringe, to a polystyrene centrifuge tube containing 0.2 ml sodium citrate buffer (0.5 M, pH 5.0). Human AB serum was separated from venous blood of fasted donors that was incubated overnight in glass at 370C. Pooled normal plasma, arbitrarily said to contain 1.00 U HF/ml, was prepared from the venous blood of 24 normal men aged 21 to 40 yr and stored at -70°C (1) . Informed consent was obtained from all subjects.
HF (Factor XII) was purified by two different methods (2, 3) , and was devoid of other clotting factors and plasminogen. It displayed a single band upon unreduced or reduced polyacrylamide gel electrophoresis. Before use, HF was diluted, usually to 0.05 U/ml, in 0.25% bovine serum albumin in barbital-saline buffer (BS-Alb).
Apparent solutions of 10-4 M ellagic acid (synthesized by Dr. James Crum in 1966 or Dr. Miklos Bodanszky in 1983, Case Western Reserve University) in BS were prepared as described earlier (2) and diluted to the desired concentration with BS.
The buffers used included BS (2), BS-Alb, tris-imidazole-saline buffer (0.025 M, pH 8.2) (4), Dulbecco's phosphate-buffered saline (DPBS) or DPBS without calcium and magnesium ions (DPBS-CaMg) (MA Bioproducts, Walkersville, MD; KC Biological, Lenexa, KA; or Gibco, Grand Island, NY) (5), DPBS with 1% bovine albumin (DPBSAlb), RPMI 1640 with 2 mM L-glutamine (RPMI) (6) , RPMI with 10% human AB serum (RPMI-HS), and RPMI with 10% fetal bovine serum (RPMI-FBS) (MA Bioproducts).
Sheep erythrocytes, suspended in Alsever's solution, were sedimented at 1,800 g at 10°C, washed three times with RPMI and suspended at a concentration of 1% (vol/vol) in RPMI.
FBS (Sterile Systems, Logan, UT) was heated at 56°C for 30 min before use.
H-D-prolyl-L-phenylalanyl-L-arginine p-nitroanilide dihydrochloride (HPPAN, S2302), benzoyl-isoleucine-glutamyl-glycyl-arginine p-nitroanilide (S2222), H-D-valyl-L-leucyl-L-lysine p-nitroanilide (S225 1), and H-D-phenylalanyl-pipecolyl-arginine p-nitroanilide (S2238) were obtained from Helena Laboratories (Beaumont, TX), dissolved at a concentration of I mM in distilled water, and stored at 4°C. Before use, HPPAN and S2238 were diluted with an equal volume of Tris-imidazole-saline buffer. N-Acetyl-L-tyrosine ethyl ester (Calbiochem, La Jolla, CA) was dissolved at a concentration of 1 M in ethyleneglycol monomethyl ester (Fisher Scientific, Fair Lawn, NJ).
Crude IgG fractions of normal goat and rabbit sera (Pel-Freez Biologicals, Rogers, AR), rabbit antiserum against human Clq (Boehringer-Mannheim Biochemicals, Houston, TX) and goat anti-scribed earlier (7, 8) . Crude IgG fractions of normal goat and rabbit sera, goat antiserum against human platelet factor 4 (PF4; Atlantic Antibodies, Scarborough, ME) and rabbit antiserum against human Cl-INH (Cl inactivator, Behring Diagnostics, La Jolla, CA) were prepared in the same way and further purified by filtration through DEAE-Affigel Blue (Bio-Rad Laboratories, Richmond, CA) and concentrated, first by negative pressure dialysis against BS and then in a Centricon 30 microconcentrator (Amicon Corp., Danvers, MA).
Other reagents used included heparin (beef lung, 100 U/ml, Upjohn Co., Kalamazoo, MI), Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, NJ), crystallized bovine serum albumin (BSA, Pentex, Miles Laboratories, Naperville, IL), bovine brain sulfatides (monogalactosyl-stearate, Supelco, Bellefonte, PA), bovine thrombin (Thrombostat, U. S. Pharmacopeia, Parke-Davis Co., Detroit, MI), and bovine trypsin (Worthington Biochemical Corp., Freehold, NJ). EDTA, lima bean trypsin inhibitor (LBTI), soybean trypsin inhibitor (SBTI), diisopropylfluorophosphate (DFP), benzamidine hydrochloride, cycloheximide and sodium azide were from Sigma Chemical Co., St. Louis, MO. Purified human Stuart factor (Factor X), activated by Russell's viper venom (Factor Xa) (9) and purified human trypsin-activated plasma thromboplastin antecedent (activated PTA, Factor XIa) (10) were the gifts of Dr. L. T. Goodnough, Case Western Reserve University. PF4
was the gift of Dr. L. Culp, Case Western Reserve University (1 1). C! (Cl esterase) was prepared as described by Donaldson (12) . Crude soybean phosphatides (Centrolex "P," the gift of Central Soya Co., Fort Wayne, IN) were suspended at 0.1% in 0.15 M sodium chloride. Peripheral blood cells were separated by modifications ofpublished methods, as described below. Before testing, the supernatant fluids of cell suspensions were filtered through Millex GV 0.22 gm filters (Millipore Corp., Bedford, MA), as described below.
Peripheral blood mononuclear cells (PBMC) and the supernatant fluids of PBMC suspensions were prepared by an adaptation of B6yum's method (13) . Typically, in replicate, 25 ml heparinized blood was diluted with 25 ml DPBS-CaMg. 10-ml aliquots were layered onto 3 ml Ficoll-Paque, and centrifuged at 450 g for 45 min. The PBMC layers were combined, washed twice with 40 ml DPBS-CaMg, once with 40 ml of an equal mixture of DPBS-CaMg and DPBS and once with 40 ml of DPBS, pelleting the cells each time at 500 g for 10 min. The washed cells, suspended in DPBS at 5 X 106/ml, were recentrifuged in the same way. The mean viability of PBMC was 93% (SD±6.8%).
The supernatant fluid was filtered through a Millex GV 0.22-gm filter unit attached to a polypropylene syringe, replacing the filter after 15 ml had been filtered. The PBMC, resuspended at 5 X 106 cells/ml, and the filtered supernatant fluid were saved. No lactic dehydrogenase was detected in the PBMC supernate in a sample containing 15 Mg protein/ml, using a method sensitive to 1 U/liter ( 14) . In some experiments, the cells were recentrifuged and resuspended repeatedly, saving successive supernatant fluids. PBMC and their supernates were tested within an hour of separation after storage in an ice-water bath.
Concentrates of the supernatant fluid of PBMC were prepared by negative pressure dialysis against DPBS, or by positive pressure filtration through an Amicon filter (ultrafiltration cell, model 8400, Amicon Corp.) fitted with a PM 10 membrane. Concentrates were made from the combined supernates of replicate preparations or from the combined supernates of successive washes of a single preparation of PBMC.
The possible presence ofC1-INH, C lq, ,B2-glycoprotein-I or PF4 in concentrated PBMC supernatant fluid (1 mg protein/ml) was examined by immunodiffusion, using 1% agar (15) . The presence of glycosaminoglycans containing uronic acid was tested by measuring the concentration of uronic acid in the same concentrate (16).
The suspensions of PBMC were contaminated with platelets. In some experiments, the proportion of platelets was reduced by -85-95% by centrifuging 25 ml of heparinized blood at 200 g for 15 min. The platelet-rich supernate was removed, and the cells were washed three times with DPBS-CaMg, centrifuging at 200 g. The platelet-depleted blood was used to prepare PBMC.
To test the effect of trypsin on the inhibitory properties of PBMC and PBMC supernate, 0.025 ml bovine trypsin (0.05 mg/ml BS) or BS was incubated with 0.1 ml PBMC, supernate or DPBS at 370C for 2 h in 12 X 75 mm polystyrene tubes. Thereafter, 0.025 ml LBTI (0.2 mg/ml BS) and 0.05 ml HF (0.1 U/ml in 0.5% BS-Alb) or BS-Alb alone, were added in rapid succession. After 10 min, the amidolytic activity of HF was measured as described below.
Ammonium sulfate-precipitable material in PBMC supernates was separated by addition of sufficient solid ammonium sulfate to provide 60% saturation. The mixture was incubated at 4VC overnight and the precipitate that formed, separated by centrifugation at 20C for 15 min at 2,000 g, was dissolved in sufficient DPBS to restore the original volume and dialyzed for I h against running tap water and overnight against -100 vol of DPBS. DFP-treated PBMC supernatant fluids were prepared by adding 1/100th vol 0.1 M DFP in isopropanol (final concentration 1 mM). The mixture was incubated for 90 min and then dialyzed against 100 vol DPBS at 4VC overnight. As a control, the supernates were treated in the same way with 1/100th vol of isopropanol. Cycloheximide-treated PBMC were prepared by suspending PBMC in RPMI at a concentration of 5 X 106 cells/ml. To one of two 12-ml aliquots, 0. 12 ml cycloheximide (5 mg/ml DPBS) was added to provide a concentration of 50 Mug/ml (18 gM). The two aliquots were incubated with mild agitation for 16 h at 37°C and the cells tested for viability. The aliquots were centrifuged for 10 min at 500 g and washed three times in DPBS. The pelleted cells were diluted in DPBS to 5 X 106/ml, recentrifuged, the supernatant fluid saved, and the cells resuspended in DPBS at 5 X 106/ml.
Sodium azide-treated PBMC were prepared by suspending PBMC in RPMI at 107 cells/ml. 9.0-ml aliquots were diluted with 9.0 ml sodium azide (10 mg/ml RPMI) or RPMI alone, incubated with mild agitation for 20 h at 37°C, washed as described for cycloheximidetreated cells, and tested for viability.
Crude Sundstrom and Nilsson (18) . The cells were washed and centrifuged for 10 min at 500 g in polystyrene tubes, the cells were then suspended successively, twice in DPBS-CaMg, once in an equal mixture of DPBS-CaMg and DPBS, and finally in DPBS, separating the cells each time by centrifugation. The final cell suspension, > 95% viable, was diluted in DPBS to 5
x 106/ml, and recentrifuged and the supernatant fluid saved.
Lymphocytes were prepared in the same manner as the monocyte-enriched cell fraction by centrifuging nonadherent PBMC at 500 g for 10 min. The cells were washed three times in DPBS, diluted to 5 X 106/ml with DPBS and resedimented at 500 g for 10 min. The supernatant fluid and the sedimented cells, resuspended in DPBS to the same concentration, were saved. Crude cytosol and particulate fractions of lymphocytes were separated as described for PBMC.
T and B lymphocytes were prepared by modifications of the methods ofGreaves and Brown (19) and Weiner et al. (20) . In brief, a cell fraction enriched in T cells was separated from a preparation of PBMC, substituting RPMI-HS for the final addition of DPBS. The cells were diluted to 10'/ml in RPMI-HS. 6 ml were transferred to each of replicate polystyrene tissue culture flasks and incubated at 370C for 1 h in a humidified atmosphere of 5% carbon dioxide and 95% air. The suspensions of nonadherent cells were removed, each flask was rinsed twice with 2.5 ml prewarmed RPMI-FBS, and the combined suspensions were centrifuged at 500 g for 10 min. The sedimented cells, suspended in 6.5 ml RPMI-FBS, were filtered through 600 mg acidwashed nylon wool (scrubbed nylon, Fenwal Laboratories, Deerfield, IL) wetted with RPMI-FBS, refiltering the cells through the same column three times. Nonadherent cells were filtered through the column by applying 10 ml RPMI-FBS, prewarmed to 370C. The effluents of three such columns were combined, centrifuged at 500 g for 10 min, the cell pellet was suspended in 6.5 ml DPBS, recentrifuged, and the pellet washed three more times with 20 ml DPBS. The cell suspension, diluted to 5 X I o6 cells/ml, was recentrifuged, the supernatant fluid was saved and the cells were resuspended to 5 X 106/ml. The proportion of T cells was identified immunologically by cytofluorography, using mouse monoclonal antibodies to the OKT 11 marker (Ortho Diagnostic Systems, Raritan, NJ) (21) .
A fraction of PBMC enriched in B cells was separated by washing the nylon wool column used to separate T cells with 50 ml RPMI-FBS and allowing the column to drain. Adherent B cells were dislodged mechanically, eluted with 5 ml RPMI, and centrifuged at 500 g for 10 min at 10C. The pelleted cells were suspended in 1 ml of RPMI-FBS, and diluted to 3 X 106 cells/ml. 1 ml ofthis crude B cell suspension was mixed with 1 ml of a 1% suspension of sheep erythrocytes in RPMI, centrifuged at 500 g for 5 min at 40C, and incubated at 4VC overnight.
The pelleted cells were resuspended and the contents of five such tubes were layered over Ficoll-Paque at a ratio of 8 ml cell suspension and 3 ml Ficoll-Paque. The tubes were centrifuged at 500 g for 30 min, the separated cell layer, enriched with B cells, was washed three times in DPBS, and the cells were diluted to 5 X 106/ml and recentrifuged. The supernatant fluid was saved and the cells were resuspended in DPBS. The proportion of B cells was identified by cytofluorography, using goat polyvalent immunoglobulin against surface immunoglobulin (PV antibodies, Kallestad Laboratories, Minneapolis, MN) (21) .
Granulocytes were separated from 25 ml heparinized venous blood by a modification of published methods (13, 22) . The blood was diluted with an equal volume of DPBS-CaMg, layered over 18 ml Ficoll-Paque, and centrifuged at 450 g for 40 min. The supernatant fluid was removed and the thin leukocyte layer, 3 ml, was transferred to each of two 50-ml sterile polystyrene centrifuge tubes. A volume of 24 ml ofdistilled water was added to each tube and, after 20 s, 8 ml of0.67 M (3.6%) sodium chloride was added rapidly to each tube and the contents mixed. The tubes were centrifuged at 250 g for 10 min at 2°C, the pelleted granulocytes were resuspended in 24 ml water and the process repeated. The cells were then suspended in 10 ml DPBS-CaMg and rewashed, twice with DPBS-CaMg, once with an equal mixture of DPBS and DPBS-CaMg, and finally with DPBS. The pelleted cells were suspended in DPBS at 5 X 106/ml. The cell suspension and the supernatant fluid after centrifugation were saved.
Erythrocytes were separated from 10 ml citrated venous blood by centrifugation at 250 g for 15 min. The supernatant, platelet-rich plasma was withdrawn and 4 ml of the pelleted erythrocytes were aspirated from the bottom ofthe tube, recentrifuged, and the bottom 3 ml of erythrocytes were withdrawn and washed three times with 3 ml DPBS, sedimenting the cells each time at 2,000 g for 10 min. The erythrocytes were then diluted to 2 X I07 cells/ml with DPBS and was recentrifuged at 2,000 g for 10 min. The supernatant fluid was removed and saved, and the erythrocytes were rediluted to 2 X 107 cells/ml. No platelets or leukocytes were seen in smeared preparations stained with Wright-Giemsa stain.
Platelets were separated from 40 ml citrated blood by a modification of Kinlough-Rathbone's (23) method. The platelet-rich plasma, sedimented at 200 g for 10 min, was recentrifuged at the same speed to reduce contamination with erythrocytes. The platelet-rich plasma was mixed with an equal volume of DPBS-Alb, incubated at 370C for 15 min and centrifuged at 1,800 g for 10 min. The pelleted platelets were washed twice more in 10 ml of DPBS-Alb and suspended in DPBS (without albumin) at 108 cells/ml. This suspension and the supernatant fluid after recentrifugation were saved. No erythrocytes or leukocytes were seen in smears of the platelet suspension stained with WrightGiemsa stain.
The effect of cell suspensions or the supernatant fluid of cells suspensions on activation of HF by ellagic acid was measured by incubating 0.1 ml HF (0.05 U/ml in BS-Alb) with 0.1 ml of the agent to be tested, diluted serially with DPBS, for 10 min at 370C in 12 X 75 mm polystyrene tubes. Thereafter, 0.05 ml ellagic acid (2 X 10-5 M in BS) was added to each tube. Incubation was continued for 60 min, after which 1.0 ml HPPAN was added. Incubation was continued for 60 min and the reaction was then stopped by addition of 0.3 ml glacial acetic acid. The amount of p-nitroaniline (p-NA) released from HPPAN was measured spectrophotometrically at 405 nm against blanks in which glacial acetic acid was added before substrate, in comparison to the OD of p-NA solutions. Mixtures containing cells were centrifuged at 800 g for 10 min before measurement of OD. Controls included the substitution of appropriate buffers for the test solution, HF, or ellagic acid. The degree of inhibition by the test solutions was determined in comparison to the amidolytic activity of a range of concentrations of HF. The coefficient of variation of the amidolytic assay of HF was 3.2% (SD±3.1%, SE±1.0%) of any given value excluding observations in which the OD was 0.010 or less. The coefficient of variation of the assay for inhibitory activity was 3.7% (SD±3.4%, SE±0.6%). Variations of this technique are described in the text. All experiments were performed in replicate.
To test the effect ofLBTI and SBTI on PBMC supernates, 0.1 ml of supernate was incubated with 0.05 ml LBTI or SBTI in BS, serially diluted with BS, for 10 min at 37°C, 0.05 ml HF (0.1 U/ml BS-Alb) was added and incubation was continued for 10 min, after which 0.05 ml 2 X lO-' M ellagic acid was added. After an additional 60 min, 1.0 ml HPPAN and 0.05 ml BS were added, and the assay continued as described above. As controls, BS was substituted for LBTI or SBTI in the initial mixture, and LBTI or SBTI was substituted for BS in the final mixture.
The effect of the supernatant fluid of cell suspensions on the activation of HF by glass was measured by mixing 0.25 ml HF (0.05 U/mI BS-Alb) or bovine albumin alone and 0.25 ml supernatant fluid, diluted serially with DPBS, or DPBS alone. Aliquots of 0.2 ml were transferred to 10 X 75 mm disposable borosilicate glass tubes (Fisher Scientific Co., Pittsburgh, PA). The tubes were incubated for 60 min at 37°C, agitating the tubes continuously in a mechanical shaker. Thereafter 0.1 ml DPBS and 1.0 ml HPPAN were added and incubation and shaking were continued for 60 min, after which 0.3 ml glacial acetic acid was added. The amount of p-NA released was measured as described above.
The capacity of PBMC supernates to inhibit the clot-promoting properties ofglass was tested by an earlier method (24) . In duplicate, 10 X 75 mm disposable glass tubes were coated with 0.2 ml samples of supernate or BS. Volumes of0.1 ml each ofnormal pooled plasma and Centrolex P were incubated in these tubes at 37°C for 1 min, and the clotting time was measured at this temperature after addition of0.1 ml 0.025 M calcium chloride, prewarmed at 37°C.
To determine whether binding took place between HF and the inhibitory agent(s) in PBMC supernates, a concentrate of PBMC supernate was bound covalently to cyanogen bromide-activated agarose (CNBr-activated Sepharose 4B, Pharmacia Fine Chemicals) according to the manufacturer's directions, at a ratio of 10 mg protein to 1 g gel. A control gel was prepared in the same way, omitting addition of PBMC supernate and blocking the active site with ethanolamine. A volume of 2 ml of gel was packed in polypropylene Econo-columns (i.d. 0.8 cm; Bio-Rad Laboratories) and washed with DPBS before use. I ml HF (1.0 U/ml BS-Alb, 48 U/mg protein) was filtered through each column, eluting with DPBS. l-ml aliquots were collected in polystyrene tubes and assayed for coagulant HF activity in comparison with that of pooled normal plasma (25) .
The effect of PBMC supernates on the coagulant action of thrombin was tested in 10 X 75 mm polystyrene tubes by measuring the clotting time at 370C of a mixture of 0.1 ml each of pooled normal human plasma, a concentrate of supernate in DPBS, and bovine thrombin (5 U/ml). The presence of fibrinogen in supernates was examined in the same way, omitting plasma. The effect of PBMC supernates on the prothrombin time and kaolin-activated partial thromboplastin time was similarly measured (25) .
The effect of PBMC supernates on the amidolytic properties of activated PTA (26) and plasmin (25) and the esterolytic properties of Cl (27) (Table I) . Platelet suspensions and their supernates inhibited activation of HF by ellagic acid, but this was significant only at relatively high concentrations of platelets (Table II) .
Comparison of the data presented in Tables I and II suggests that a portion of the inhibitory effect of PBMC suspensions was due to their content of platelets. When PBMC were prepared from normal human blood that had been depleted of -95% of its platelet content, inhibition of the activation of HF by PBMC was reduced by -50%, and by the supernates of PBMC suspensions by -75%. Thus, a significant portion of the inhibitory properties of PBMC suspensions could be attributed to platelets. That platelets were not solely responsible for the inhibitory properties of PBMC suspensions was demonstrated in studies of PBMC prepared from the blood of a patient with severe thrombocytopenia. At concentrations of platelets that were not inhibitory (Table II) , both the cell suspension and the supernatant fluid inhibited activation of HF (Table I) .
The PBMC were mixtures of -80% lymphocytes and 20% monocytes. A monocyte-enriched fraction of PBMC, prepared from platelet-depleted blood, and the supernate ofthis fraction inhibited activation of HF (Table III) . Similarly, the supernatant fluid of a suspension of cultured monocytoid cells (U937) inhibited activation of HF (Table III) .
A lymphocyte-enriched fraction of PBMC, prepared from blood that had been depleted of platelets, and the supernate of this fraction inhibited the activation of HF (Table III) . Both T and B lymphocytes and their supernates were inhibitory (Tables III and III) .
The inhibitory properties ofgranulocytes and erythrocytes and their supernatant fluids on the activation ofHF by ellagic acid. Granulocytes, separated as described, and the supernatant fluid of granulocyte suspensions inhibited activation of HF to approximately the same degree as PBMC suspensions (Table IV) .
Neither erythrocytes nor the supernatant fluid of erythrocyte suspensions had significant inhibitory properties (Table IV).
Some properties ofthe inhibitory activity ofPBMC supernates. The inhibitory properties of PBMC suspensions and their supernates were directed against the activation of HF and not at the amidolytic properties of activated HF. Addition of cells or supernatant fluid after HF had been incubated with ellagic acid for 60 min was without effect; the cells and supernatant fluid themselves did not have amidolytic properties for this substrate (Table I) .
After ultracentrifugation, both the cytosol and particulate fractions of PBMC inhibited the activation of HF by ellagic acid, but in repeated experiments the cytosol appeared to be relatively more inhibitory (Table V) . Similarly, both cytosol and particulate fractions of lymphocytes and monocytes were inhibitory (data not shown).
The inhibitory properties of PBMC supernates were not reduced by filtration of supernates through a Millex-GV filter, said to retain particles > 0. 22 Am diam), nor by dialysis through casings with a mol wt cut-off of 12-14,000.
The inhibitory properties of PBMC supernates were re- Binding of HF to the inhibitory agent(s) in PBMC supernates could not be demonstrated. The coagulant titer of HF was the same, whether filtered through a column of agarose to which PBMC supernate had been covalently linked, or through a control column of agarose.
Incubation of PBMC or PBMC supernates with trypsin reduced their inhibitory properties, suggesting that a protein component participated in inhibition of the activation of HF (Table VI) . In agreement with this interpretation, approximately half of the inhibitory properties of PBMC supernates were precipitated by ammonium sulfate at 60% saturation.
No evidence was obtained that the inhibitory properties of PBMC supernatant fluids were enzymatic. The inhibitory properties of PBMC supernate appeared to be essentially instantaneous (Fig. 1) . When PBMC supernate was incubated Amidolytic activity generated in a mixture of HF, test mixture (serially diluted with DPBS) and ellagic acid (see Methods). The test mixtures in A were polystyrene-adherent cells, at an initial concentration of 5 X 106 cells/ml, prepared from PBMC that had been separated from platelet-depleted blood, and the supernate of the initial adherent cell suspension; the adherent cell suspension contained 94% monocytes, 6% lymphocytes and 2.3 X 10' platelets/ml or 4.6 platelets per adherent cell. The test mixture in B was the supernate of a suspension of human monocytoid cells (U-937) containing 5 X 106 cells/ml. The text mixtures in C were nonadherent cells, at an initial concentration of 5 X 106 cells/ml, prepared from PBMC that had been separated from platelet-depleted blood, and the supernate of the initial nonadherent cell suspension; the nonadherent cell suspension contained 1.5 , after which 0.1 ml HF (0.05 U/ml, 58 U/mg protein) was added. The mixture was incubated for an additional 60 min, 1.0 ml HPPAN was added, and incubation was continued for 60 min (!). Conversely, 0.1 ml supernate was incubated with 0.1 ml HF for lO s to 40 min, after which 0.5 ml ellagic acid was added and the procedure continued as before (o). The reaction was stopped by addition of 0.3 ml glacial acetic acid and the amount ofp-NA released was measured (see Methods). The amidolytic activity generated in mixtures of 0.1 ml HF and 0.1 ml DPBS, incubated for 10 s to 40 min before addition of ellagic acid, was also measured (x). (Table VII) . (Table VII) . At very high concentrations, PBMC supernates had some inhibitory activity against human urokinase-activated plasmin; a preparation of PBMC supernate (508 ,ug protein/ml) reduced the amidolytic activity of this enzyme from 37.0 to 29.4 nmol p-NA released/ml per h by the method described.
Incubation of PBMC for 16 h with cycloheximide (50 ,gg/ml) sharply reduced the inhibitory properties of PBMC supernates, which contained strikingly less protein than the supernates of untreated cells, as though protein synthesis had been depressed (Table VIII) . Similarly, PBMC treated with cycloheximide were less inhibitory than untreated cells, but the difference was less pronounced.
Incubation of PBMC overnight with sodium azide at a (2) . The supernates of PBMC inhibited activation of HF by sulfatides, but only at higher protein concentrations than needed to inhibit ellagic acid (Table IX) .
Discussion
A remarkable property ofperipheral blood, much pondered in the nineteenth century, is that the circulating blood is fluid, yet clots promptly when it is withdrawn from blood vessels and transferred to glass tubes. One mechanism through which this comes about is the transformation of Hageman factor (HF, Factor XII) to an enzymatically active state upon contact with certain negatively charged agents (36). Equally remarkable is that the continual contact of plasma with biologically active blood cells does not initiated the clotting process. The experiments that have been described provide some clues to this puzzle, for suspensions of PBMC, including monocytes, lymphocytes (both T and B cells), neutrophils, and to a lesser extent platelets, all appeared to retard the activation of HF by ellagic acid, an agent that in apparent solution readily converts this clotting factor to its activated form. The supernatant fluids in which these cells were suspended shared this property, as if one or more inhibitors of the activation of HF were eluted from the cells. Indeed, since in this study the cells were necessarily suspended in an aqueous medium, it is possible that all ofthe results described were due to the presence ofthese inhibitory substances in the fluid phase.
Experiments were performed to determine whether the inhibitory properties of PBMC, monocytes, lymphocytes, and granulocytes were due to contamination with platelets. Preparing PBMC from the blood ofa patient with aplastic anemia did not alter the result, nor did partial reduction ofthe platelet contamination of preparations of PBMC, lymphocytes, and granulocytes. Moreover, supernates of cultured monocytoid cells, uncontaminated with platelets, inhibited activation of HF by ellagic acid.
The nature of the inhibitory agent or agents eluted from cells was only poorly defined. Several Some years ago, the plasma ofpatients with Hageman trait or with hereditary deficiency of plasma prekallikrein (Fletcher trait) was found to contain agents that were adsorbed to a glass surface, where they reduced the clot-promoting properties of glass (34, 35) . Similar agents were also demonstrated in fractions of normal plasma (24) . We were, however, unable to demonstrate that the inhibitory properties of PBMC supernates were adsorbed to glass surfaces, suggesting that the supernates contained an agent or agents different from those found in human plasma. Two specific protein components of plasma that inhibit the activation of HF have been identified, ft2-glycoprotein-I (32) and Clq (33) . Although this might suggest that the inhibitory property of blood cells may have been due to the selective adsorption of these plasma agents to the cell surface, this did not appear to be the case, for we were unable to demonstrate their presence in concentrates ofPBMC supernates by immunodiffusion studies against specific antisera. Another plasma protein, C1 inhibitor (C1-INH), inhibits activated HF (37), whereas PBMC supernates appeared to inhibit the activation of this clotting factor; the presence of CI-INH in PBMC supernates could not be demonstrated either functionally or by immunodiffusion against specific antiserum.
Cell walls are rich in proteoglycans. It is unlikely that the presence of these substances in PBMC supernates was responsible for their inhibitory effects, since proteoglycans and their constituent glycosaminoglycans are activators, rather than inhibitors of Hageman factor (38, 39) . No uronic acid could be demonstrated in concentrates of PBMC supernates, but this does not exclude the possibility that proteoglycans not containing uronic acid were present.
Because the preparations of PBMC studied were contaminated with platelets, the possibility that the phenomena observed were due to PF4 was of interest. PF4 is known to block activation of the contact system (40 
